Breaking Finance News

Abaxis (NYSE:ABAX) has been downgraded from Buy to Neutral in a statement by Northcoast Research earlier today.

Yesterday Abaxis (NYSE:ABAX) traded -1.19% lower at $51.54. The company’s 50-day moving average is $50.70 and its 200-day moving average is $49.22. The last closing price is up 4.82% from the 200-day moving average, compared to the S&P 500 which has decreased -0.03% over the same time period. 225,308 shares of the stock traded hands, up from an average trading volume of 141,056

Northcoast Research has downgraded Abaxis (NYSE:ABAX) from Buy to Neutral in a report released on 11/30/2016.

Previously on 2/03/2016, Credit Suisse reported on Abaxis (NYSE:ABAX) increased the target price from $0.00 to $39.00. At the time, this indicated a possible downside of -0.08%.

See Chart Below

Abaxis (NYSE:ABAX)

Abaxis has a 52 week low of $37.71 and a 52 week high of $58.15 with a P/E ratio of 33.46 The company’s market cap is currently $0.

In addition to Northcoast Research reporting its stock price target, a total of 6 brokers have issued a research note on the company. The average stock price target is $53.42 with 2 brokers rating the stock a strong buy, 0 brokers rating the stock a buy, 6 brokers rating the stock a hold, 1 broker rating the stock a underperform, and finally 0 brokers rating the stock a sell.

General Information About Abaxis (NYSE:ABAX)

Abaxis, Inc. is a developer, manufacturer and marketer of portable blood analysis systems that are used in medical specialties in human or veterinary patient care to provide clinicians with blood constituent measurements. The Company markets and sells its products around the world through independent distributors and direct sales force. The Company's segments are the medical market and the veterinary market. The Company's medical market products include Piccolo chemistry analyzers and consumable products. The Company develops, manufactures and sells the Piccolo Xpress chemistry analyzer for use in human patient care to provide clinicians with blood constituent measurements. The Company's veterinary market product offerings include VetScan chemistry analyzers and veterinary reagent discs, VetScan hematology instruments and related reagent kits, VetScan VSpro specialty analyzers and related consumables, VetScan i-STAT analyzers and related consumables and VetScan rapid tests.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *